34. CHARACTERISTICS OF EGFR MUTATIONS IN PATIENTS WITH ADENOCARCINOMA LUNG CANCER UNDERGOING SURGERY AT NATIONAL LUNG HOSPITAL IN 2022
Main Article Content
Abstract
Background: Lung cancer is increasingly being detected early, and surgical treatment has a very high survival rate of over 5 years. However, there are still some recurrences after surgery, leading to changes in treatment strategies before and after surgery. In addition to chemotherapy, there are also immunotherapy methods and tyrosine kinase inhibitors. In particular, EGFR mutation testing plays an important role in providing treatment strategies before and after surgery.
Objective: Evaluate gene mutation testing in adenocarcinoma lung cancer patients treated surgically at the National Lung Hospital.
Subjects and methods: Lung cancer patients diagnosed by histopathology. In which, EGFR gene mutations were determined using Viennalab's Strip Assay method from biopsy or surgical specimens at the Department of Pathology of the National Lung Hospital.
Results: 40 patients were tested for EGFR gene mutations. Among them, 24/40 patients were EGFR positive. 9 patients are positive on Exon 19, 15 patients are positive on Exon 21
Conclusion: From the above results, it shows that EGFR mutation testing in lung cancer patients and the possibility of surgery is a factor in assessing prognosis and providing treatment possibilities before and after surgery.
Article Details
Keywords
Non-small cell lung cancer, EGFR gene mutation
References
resectable non-small-cell lung cancer: where is it
going?." Annals of Oncology 21 (2010): vii196-vii198.
[2] Kratz, Johannes R., et al. "A practical molecular
assay to predict survival in resected non-squamous,
non-small-cell lung cancer: development
and international validation studies." The Lancet
379.9818 (2012): 823-832.
[3] Pignon, Jean-Pierre, et al. "Lung adjuvant cisplatin
evaluation: a pooled analysis by the LACE
Collaborative Group." Database of Abstracts of
Reviews of Effects (DARE): Quality-Assessed
Reviews [Internet]. Centre for Reviews and
Dissemination (UK), 2008.
[4] Wu, Yi-Long, et al. "Osimertinib in resected EGFR-
mutated non–small-cell lung cancer." New
England Journal of Medicine 383.18 (2020):
1711-1723.
[5] Xu L, Li C, Lu H. Invasive mucinous adenocarcinoma
of the lung. Transl Cancer Res. 2019 Dec;8(8):2924-2932
[6] Cha YJ, Shim HS. Biology of invasive mucinous
adenocarcinoma of the lung. Transl Lung Cancer
Res 2017;6(5):508-512.
[7] Fujimoto D(1), Ueda H, Shimizu R, Kato R,et
al (2014). Features and prognostic impact of
distant metastasis in patients with stage IVlung
adenocarcinoma harboring EGFR mutations:
importance of bone metastasis.Clin Exp Metastasis.
31(5):543-51.
[8] Hondelink, Liesbeth M., et al. "Prevalence,
clinical and molecular characteristics of early
stage EGFR-mutated lung cancer in a real-life
West-European cohort: Implications for adjuvant
therapy." European Journal of Cancer 181(2023): 53-61.
[9] Li, Ming, et al. "Pan-driver-negatives versus
epidermal growth factor receptor mutants for
C-stage IA lung adenocarcinoma with groundglass
opacity." Annals of Thoracic and Cardiovascular Surgery
28.5 (2022): 320-328.